GET LINCKR

Alentis Therapeutics Company Contacts

Alentis Therapeutics

https://alentis.ch
Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis.  Alentis is pioneering a novel approach to modify and reverse the course of disease progression... Read More
Contacts

Country

Switzerland

City

Allschwil

Headquarters

Allschwil, Basel-Country

LinkedIn

Profile

Founded

2019

Industry

Pharmaceutical Manufacturing

Size

51 - 200

Specialties

Claudin-1, CLDN1, Claudin, Oncology, Cancer, Kidney Fibrosis, Rare Diseases, Nephrology, Lung Fibrosis, Liver Fibrosis, ALE.C04, ALE.F02, Drug Development, Drug Discovery, Pulmonology, Hepatology, Fibrosis, Antibody-drug conjugates, ADC, HNSCC, Idiopathic pulmonary fibrosis, ANCA-associated vasculitis

Funding

Total Rounds

4

Last Round

Thu Apr 27 2023

Last Round Series

Grant

Last Round Raised

No Data